Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Lantheus Holdings Appoints Dr Jeffrey Humphrey As Chief Medical Officer and Dr Jean Claude Provost As Chief Science Officer

PUBLIC · LNTHMay 16, 2024•about 2 years ago

Position

Chief Science Officer

Company

Lantheus

Jean -Claude Provost

BedfordBiotechnologyHealth CareTherapeutics

Description

Lantheus Holdings has appointed Dr Jeffrey Humphrey as chief medical officer (CMO) and Dr Jean-Claude Provost as chief science officer (CSO), effective May 28, 2024.

Company Information

Company

Lantheus

Location

Bedford, Massachusetts, United States

About

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Lantheus's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months